Rob earned his Doctor of Pharmacy Degree (PharmD) from Duquesne University and his Doctor of Philosophy (PhD) in Pharmaceutical Sciences from the University of North Carolina in Chapel Hill. Rob has over 16 years of experience in formulation development at Bristol Myers Squibb and is known as an expert in improving oral bioavailability by particle size reduction, amorphous technologies, and solubilization approaches including lipid-based delivery. Rob currently leads a team of formulators responsible for small molecule oral and parenteral early-stage portfolio from nomination through FIH including IND-enabling GLP and chronic toxicology, FIH, ADME, and Absolute Bioavailability formulations development. Rob is the Principal Investigator for two grants through ISSNL, including “Structural and Crystallization Kinetics Analysis of Monoclonal Antibodies”, which launched on SpaceX-21 in December 2020 and “Screening and Batch Manufacture of Complex Biotherapeutics in Microgravity”, which launched on SpaceX-27 in March 2023.